Rapid growth continues for Sistemic
Jan 12, 2012Sistemic, the stem cell and drug development technology company, has won a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise. The grant forms part of a £1M planned investment programme which, on the back of a very successful year for the company, will see Sistemic more than double the size of its operation. To accommodate the expanded research team, the company is relocating to customised laboratories during the first half of 2012...
Maximise the potential of your stem cell applications
Nov 29, 2011Dr Verna McErlane, Director of Commercial Operations, International at Sistemic, is scheduled to give her own special insight into advanced analytical models to support the stem cell therapy industry at this year's Stem Cell Meeting on the MESA conference. Participants will have the opportunity to discuss miRNA profiling and learn how to maximise the potential of stem cell applications. The 2011 conference will be held in the Salk Institute for Biological Studies in La Jolla, California...
Sistemic presents the solution for broader stem cell therapy at AUSBiotech 2011
Oct 18, 2011Verna McErlane, Director of Commercial Operations for miRNA specialist Sistemic, is attending AUSBiotech 2011 in Adelaide, South Australia, 16-19 October. At this event she presented a talk entitled ‘The Challenges of Advancing Stem Cell Therapies into the clinic; a Characterisation Perspective'. The presentation formed part of the ‘Human Health - Clever cell culture for the innovation of biologics' session on 18 October...
Sistemic highlights the need for better cell characterisation in regenerative medicine
Oct 3, 2011Sistemic, the cell characterisation problem-solving service provider that uses miRNA, is a strong advocate for the potential of regenerative medicine. Dr Verna McErlane, Sistemic's Director of Commercial Operations, recently took part in a round-table discussion with leading stem cell researchers http://www.sistemic.co.uk/publications. The scientific, ethical and moral debate about the use of stem cells continues and will soon be taken up in earnest at the World Stem Cell Summit, taking place from 3-5 October in Pasadena, California, where Dr McErlane is a key participant...
Sistemic supports Talent Scotland
Sep 22, 2011Sistemic, a growing and successful biotechnology company, recently recruited a new Senior Bioinformatician with Talent Scotland's help. Sistemic and Talent Scotland share a mutual goal of attracting ‘new blood' from the international life science market to Scotland...
Growth at Sistemic Ltd due to success of unique miRNA analytical approach
Sep 12, 2011The success of the unique analytical approach brought to microRNA (miRNA) profiling technologies by Scottish-based, Sistemic Ltd., (Glasgow, UK) has led to sustained interest from the drug discovery and cell therapeutics markets. As a result the company has commenced an expansion programme which will see the addition of a number of key scientific and bioinformatic staff and a move to a larger dedicated facility near Glasgow, which will also form the company's new global headquarters...
Cell characterisation experts Sistemic join the Alliance for Regenerative Medicine
Sep 8, 2011Sistemic Ltd, a fast growing company focused on providing innovative microRNA-based (miRNA) problem-solving services to areas of unmet need within the Cell Therapy/Regenerative Medicine markets and pharmaceutical and biotechnology R&D, is delighted to announce they have joined the Alliance for Regenerative Medicine (ARM). Founded in 2009, the Alliance has more than 80 members, who span research institutes, foundations, companies and investor groups. Their aim is to advance regenerative medicine by representing and supporting members in front of government agencies and the general public...
Sistemic shares its views on the cell therapeutics industry
Jul 27, 2011Dr Verna McErlane, Director of Operations at Sistemic Ltd., a leading miRNA-based product company, has recently shared her perspective of the Cell Therapy Industry (CTI) by writing an article for the European Biopharmaceutical Review (EBR), a noted publication supporting the biopharmaceutical industry...
Sistemic is delighted to announce that its proprietary technology (SistemQCTM) has been chosen to form a key part of the research and production process for a landmark multinational collaborative project led by TiGenix, Belgium and including partners from Spain, France, the Netherlands as well as the UK and Belgium. The project, REGENER-AR, will bring the first stem cell therapy product for rheumatoid arthritis, Cx611, through final research and clinical development...
Sistemic, the stem cell and drug development technology company, has won a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise. The grant forms part of a £1M planned investment programme which, on the back of a very successful year for the company, will see Sistemic more than double the size of its operation. To accommodate the expanded research team, the company is relocating to customised laboratories during the first half of 2012...
Sistemic, the cell characterisation problem-solving service provider that uses miRNA, is a strong advocate for the potential of regenerative medicine. Dr Verna McErlane, Sistemic's Director of Commercial Operations, recently took part in a round-table discussion with leading stem cell researchers http://www.sistemic.co.uk/publications. The scientific, ethical and moral debate about the use of stem cells continues and will soon be taken up in earnest at the World Stem Cell Summit, taking place from 3-5 October in Pasadena, California, where Dr McErlane is a key participant...
Dr Verna McErlane, Director of Operations at Sistemic Ltd., a leading miRNA-based product company, has recently shared her perspective of the Cell Therapy Industry (CTI) by writing an article for the European Biopharmaceutical Review (EBR), a noted publication supporting the biopharmaceutical industry...